Gyre Therapeutics swings to Q3 net loss of $2.48 million
GYRE•Gyre Therapeutics reported a third-quarter 2026 net loss of $2.48 million, compared with a year-earlier profit. Revenue rose to $32.93 million, and full-year revenue guidance remained $100.5 million to $111 million.
1. Quarterly results and outlook
Gyre Therapeutics swung to a third-quarter 2026 net loss of $2.48 million from a year-earlier profit, while revenue rose to $32.93 million. General and administrative expense increased 39% to $8.92 million year over year. A decision from the NMPA on F351 is expected by the end of 2026 or in the first quarter of 2027; launch is anticipated in the first half of 2027 if approved. Full-year 2026 revenue guidance was unchanged at $100.5 million to $111 million.
